



Newly Reported Drugs: The following drugs were reported to NFLIS-Drug for the first time between **April 1, 2020, and June 30, 2020**, and were submitted to a NFLIS participating laboratory on or after April 1, 2019.


Northeast




4-Anilino-1-Boc-piperidine



2-Fluoro viminol




ADB-BUTINACA



South

MMB-4en-PINACA



Snapshot of Drug Reports Received by NFLIS-Drug

The tables on the right present the top five drug reports in each category received by NFLIS-Drug between April 1, 2020, and June 30, 2020, that were submitted to a NFLIS participating laboratory on or after April 1, 2019.



¹ BMDP = 3,4-Methylenedioxy-N-benzylcathinone.

² Includes all positional and nonspecified isomers as reported by participating laboratories.

Top 5 Reported Drugs	257,376	Synthetic Cathinones	2,820	Selected Benzodiazepines	10,796
Methamphetamine	115,410	Eutylone	2,116	Flualprazolam	963
Cannabis/THC	54,601	N-Ethylpentylone	135	Etizolam	832
Cocaine	39,891	BMDP ¹	135	Clonazolam	195
Heroin	25,263	Butylpentylone ²	99	Flubromazolam	81
Fentanyl	22,211	alpha-PiHP	83	Adinazolam	65
Synthetic Cannabinoids	4,237	Narcotic Analgesics	16,953	Other Selected Drugs	4,507
Fluoro-MDMB-PICA ²	1,884	Oxycodone	4,820	MDMA	1,478
Fluoro-MDMB-BINACA ²	633	Buprenorphine	4,780	Gabapentin	968
MDMB-4en-PINACA	445	Hydrocodone	3,085	Lysergic acid diethylamide (LSD)	957
Fluoro-ADB ²	98	Tramadol	1,721	Psilocin	825
FUB-AMB	96	Morphine	760	Xylazine	279

Emerging Drug Trends

The charts below depict the number of reports (y axis) for selected emerging drugs that were submitted to a NFLIS participating laboratory from November 2018 through March 2020 and received by NFLIS-Drug by June 30, 2020.



Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in July 2020 and include drug reports received by NFLIS-Drug through the end of June 2020. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.deadiversion.usdoj.gov/Reports.aspx>. Questions and comments: DEANFLIS@rti.org

